CA3070442A1 - Methods of protecting vascular integrity induced by targeted radiation therapy - Google Patents
Methods of protecting vascular integrity induced by targeted radiation therapy Download PDFInfo
- Publication number
- CA3070442A1 CA3070442A1 CA3070442A CA3070442A CA3070442A1 CA 3070442 A1 CA3070442 A1 CA 3070442A1 CA 3070442 A CA3070442 A CA 3070442A CA 3070442 A CA3070442 A CA 3070442A CA 3070442 A1 CA3070442 A1 CA 3070442A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- minutes
- radiation therapy
- tpo mimetic
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1094—Shielding, protecting against radiation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Radiation-Therapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537049P | 2017-07-26 | 2017-07-26 | |
| US62/537,049 | 2017-07-26 | ||
| PCT/US2018/043821 WO2019023418A1 (en) | 2017-07-26 | 2018-07-26 | METHODS FOR PROTECTING VASCULAR INTEGRITY INDUCED BY TARGETED RADIOTHERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3070442A1 true CA3070442A1 (en) | 2019-01-31 |
Family
ID=63165522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3070442A Pending CA3070442A1 (en) | 2017-07-26 | 2018-07-26 | Methods of protecting vascular integrity induced by targeted radiation therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12251424B2 (https=) |
| EP (1) | EP3658191A1 (https=) |
| JP (1) | JP7481252B2 (https=) |
| KR (1) | KR102688415B1 (https=) |
| CN (1) | CN111432845B (https=) |
| AU (1) | AU2018306329B8 (https=) |
| BR (1) | BR112020001367A2 (https=) |
| CA (1) | CA3070442A1 (https=) |
| IL (1) | IL272213A (https=) |
| PH (1) | PH12020500166A1 (https=) |
| WO (1) | WO2019023418A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021008943A (es) * | 2019-01-25 | 2021-11-04 | Janssen Pharmaceutica Nv | Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos. |
| CN113402614A (zh) * | 2021-04-22 | 2021-09-17 | 山东泉港药业有限公司 | 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用 |
| CN119654158A (zh) * | 2022-05-20 | 2025-03-18 | 詹森药业有限公司 | 用于减轻与暴露于辐射和/或辐射或拟辐射治疗相关的肺损伤的方法 |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
| WO2025002113A1 (zh) * | 2023-06-26 | 2025-01-02 | 上海济煜医药科技有限公司 | 一种人血小板生成素受体激动剂的融合蛋白 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680422B2 (en) | 1992-06-11 | 1997-07-31 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US6083913A (en) * | 1995-06-07 | 2000-07-04 | Glaxo Wellcome Inc. | Peptides and compounds that bind to a thrombopoietin receptor |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ES2781475T3 (es) | 2002-09-18 | 2020-09-02 | Janssen Pharmaceuticals Inc | Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas |
| US7723295B2 (en) | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
| SG131110A1 (en) | 2003-08-28 | 2007-04-26 | Ortho Mcneil Pharm Inc | Peptides and compounds that bind to thrombopoietin receptors |
| US20060210542A1 (en) | 2004-08-16 | 2006-09-21 | Yurkow Edward J | Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia |
| US7615533B2 (en) | 2004-08-16 | 2009-11-10 | Janssen Pharmaceutica N.V. | TPO peptide compounds for treatment of anemia |
| EP1986677A2 (en) * | 2006-01-25 | 2008-11-05 | Amgen Inc. | Thrombopoietic compounds |
| DK1984014T3 (da) | 2006-02-14 | 2014-09-15 | Janssen Pharmaceutica Nv | Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi |
| CN100391474C (zh) * | 2006-06-13 | 2008-06-04 | 卢建军 | 用于治疗血小板减少的注射用药物 |
| CA2670345A1 (en) | 2006-12-01 | 2008-06-12 | Stategics, Inc. | Thrombopoietin mimetics |
| US8383124B2 (en) | 2008-03-12 | 2013-02-26 | Children's Hospital Medical Center | Mobilization of hematopoietic stem cells |
| ES2729622T3 (es) | 2008-06-03 | 2019-11-05 | Janssen Pharmaceutica Nv | Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer |
| JP2012518408A (ja) | 2009-02-24 | 2012-08-16 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体 |
| JP2012250880A (ja) | 2011-06-03 | 2012-12-20 | Semiconductor Energy Lab Co Ltd | グラフェン、蓄電装置および電気機器 |
| US20140047572A1 (en) | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
| US20140051631A1 (en) | 2012-08-17 | 2014-02-20 | Francoise Porteu | Pharmaceutical composition comprising tpo or an agonist of the tpo receptor |
| JP6150374B2 (ja) | 2012-11-15 | 2017-06-21 | 国立大学法人弘前大学 | 放射線被ばく治療剤及び放射線被ばく治療方法 |
| WO2020154637A1 (en) | 2019-01-25 | 2020-07-30 | Janssen Pharmaceutica Nv | Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure |
| MX2021008943A (es) | 2019-01-25 | 2021-11-04 | Janssen Pharmaceutica Nv | Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos. |
-
2018
- 2018-07-26 AU AU2018306329A patent/AU2018306329B8/en not_active Ceased
- 2018-07-26 EP EP18752969.8A patent/EP3658191A1/en not_active Withdrawn
- 2018-07-26 JP JP2020503928A patent/JP7481252B2/ja active Active
- 2018-07-26 CA CA3070442A patent/CA3070442A1/en active Pending
- 2018-07-26 BR BR112020001367-6A patent/BR112020001367A2/pt unknown
- 2018-07-26 US US16/633,854 patent/US12251424B2/en active Active
- 2018-07-26 WO PCT/US2018/043821 patent/WO2019023418A1/en not_active Ceased
- 2018-07-26 CN CN201880062272.0A patent/CN111432845B/zh active Active
- 2018-07-26 KR KR1020207005448A patent/KR102688415B1/ko active Active
-
2020
- 2020-01-23 PH PH12020500166A patent/PH12020500166A1/en unknown
- 2020-01-23 IL IL272213A patent/IL272213A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018306329A8 (en) | 2025-02-20 |
| WO2019023418A1 (en) | 2019-01-31 |
| AU2018306329B2 (en) | 2024-09-19 |
| JP7481252B2 (ja) | 2024-05-10 |
| CN111432845B (zh) | 2024-02-06 |
| KR20200059213A (ko) | 2020-05-28 |
| US12251424B2 (en) | 2025-03-18 |
| KR102688415B1 (ko) | 2024-07-24 |
| CN111432845A (zh) | 2020-07-17 |
| JP2020528903A (ja) | 2020-10-01 |
| US20200164039A1 (en) | 2020-05-28 |
| BR112020001367A2 (pt) | 2020-08-11 |
| EP3658191A1 (en) | 2020-06-03 |
| AU2018306329A1 (en) | 2020-02-13 |
| PH12020500166A1 (en) | 2020-09-14 |
| AU2018306329B8 (en) | 2025-02-20 |
| IL272213A (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018306329B8 (en) | Methods of protecting vascular integrity induced by targeted radiation therapy | |
| RU2016101057A (ru) | Лечение рака головного мозга онколитическим аденовирусом | |
| Palmowski et al. | Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions | |
| US20220168392A1 (en) | Methods of Enhancing Protection Against Organ and Vascular Injury, Hematopoietic Recovery and Survival in Response to Total Body Radiation/Chemical Exposure | |
| Patenaude et al. | Injectable oxygen microparticles boost Radiation–Mediated in situ vaccination and systemic antitumor immune responses | |
| US20070010438A1 (en) | Tumor treatment using beta-sheet peptides and radiotherapy | |
| US20230233705A1 (en) | Gold nanoparticle-containing medicine | |
| JP2025037963A (ja) | 放射性微粒子の腫瘍内沈着によるがんの処置方法 | |
| US20100035952A1 (en) | Radiosensitizer Formulations and Methods for Use | |
| HK40033362A (en) | Methods of protecting vascular integrity induced by targeted radiation therapy | |
| US20250312417A1 (en) | Methods for Mitigating Lung Injury in Conjunction with Exposure to Radiation and/or Radiation or Radiomimetic Treatments | |
| Jensen et al. | Clinical Update: treatment of glioblastoma multiforme with radiolabeled antibodies that target tumor necrosis | |
| US9440914B2 (en) | Method for treating glioblastomas and other tumors | |
| Nicholson et al. | 576: Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach | |
| Miyagi et al. | 574: Cellular Interaction Between Prostate Cancer and Bone Stroma: Effects of Radiation on the Growth and Colonization of Human Prostate Cancer Cells in Bone | |
| Werahera et al. | 575: Proliferative Tumor Doubling Times of Prostatic Carcinoma Measured by in Vivo Bromodeoxyuridine (BRDU) Labeling and Flow Cytometric Analysis | |
| CA2494209A1 (en) | Radiosensitizer formulations and methods for use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220208 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED Effective date: 20250327 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250327 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250603 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250603 |